← All trials
NCT02652130
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 28, 2015
- Primary completion
- Jun 15, 2018
- Completion date
- Jun 15, 2018
- First posted
- Jan 11, 2016
- Last posted
- Mar 16, 2022
- Enrollment
- 32
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Mesoblast, Inc.Lead sponsor
- Mesoblast, Inc.Study director
- IQVIACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.